Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
Information source: New York University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Avascular Necrosis
Intervention: Atorvastatin (Drug); MRI, Venipuncture (Procedure)
Phase: Phase 2
Status: Terminated
Sponsored by: New York University School of Medicine Official(s) and/or principal investigator(s): Howard M Belmont, M.D., Principal Investigator, Affiliation: The New York University Hospital for Joint Diseases
Summary
This study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show
reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a
disease resulting from the loss of blood supply to the bones which can cause the bone to
collapse. The collapse of bone may require a surgical replacement of the joint and can be
disabling for life. Avascular necrosis is presently not preventable but research has shown
that lipid lowering drugs such as lipitor can reduce or prevent avascular necrosis in
animals. We therefore hypothesize that lipitor will reduce the incidence of avascular
necrosis in lupus patients taking high dose steroids.
Clinical Details
Official title: AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Primary outcome: A goal of 50% reduction of new AVN with atorvastatin assuming 50% of patients will develop at least one new site of AVN
Secondary outcome: To determine if atorvastatin is effective in lowering serum lipid levels Chol, TG, HDL, & LDL in SLE patientsTo determine if atorvastatin has an anti-inflammatory effect in active SLE that reduces biological markers of the inflammatory process (ESR, hs-CRP) and reduces disease activity assessed by serology (C3, C4, anti-dsDNA) or clinical instrument (SLEDAI)
Detailed description:
If you have started on prednisone 30mg or greater and expect to be on it for greater than
two weeks you may be a candidate for the study. Also, you would need to be enrolled in the
study within three days of starting prednisone. If you are eligible you will receive lipitor
40mg per day or pills which look exactly like lipitor but do not contain any medication
(called placebo). During the time of the study, you will not know if you are taking lipitor
or the placebo. The period of time that you will receive lipitor or placebo is 9 months and
you must be willing to return for 5 follow up visits during this time which include blood
tests, physical exams and 3 MRI studies of the hips, knees and ankles.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- All individuals must fulfill 4 of the revised criteria of the American College of
Rheumatology for SLE
- Patient started on corticosteroids at a dose of at least .5mg/kg for an interval
greater than two weeks
- To be able to come for all follow-up visits for nine months
- No contraindications to undergoing MRI
- Age 18-75 years
Exclusion Criteria:
- Evidence of liver disease, not secondary to active lupus, or liver enzyme greater
than 2x normal
- Elevated CPK at baseline
- Pregnancy or Lactating
- Allergy to a statin
- Current or recent use of a statin within 3 months
Locations and Contacts
The New York University Hospital For Joint Diseases, New York, New York 10003, United States
Additional Information
Related publications: Belmont HM, Lydon E. Avascular necrosis prevention with lipitor in lupus erythematosus. Lupus. 2005;14(10):869-70.
Starting date: November 2002
Last updated: January 17, 2013
|